These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28733862)

  • 1. Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.
    Devanarayan V; Smith WC; Brunelle RL; Seger ME; Krug K; Bowsher RR
    AAPS J; 2017 Sep; 19(5):1487-1498. PubMed ID: 28733862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.
    Kloks C; Berger C; Cortez P; Dean Y; Heinrich J; Bjerring Jensen L; Koppenburg V; Kostense S; Kramer D; Spindeldreher S; Kirby H
    J Immunol Methods; 2015 Feb; 417():1-9. PubMed ID: 25602137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation.
    Su C; Zhou L; Hu Z; Weng W; Subramani J; Tadkod V; Hamilton K; Bautista A; Wu Y; Chirmule N; Zhong ZD
    J Immunol Methods; 2015 Oct; 425():88-96. PubMed ID: 26130368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
    Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
    J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harmonization and standardization of immunogenicity assessment of biotherapeutic products.
    Wadhwa M; Thorpe R
    Bioanalysis; 2019 Sep; 11(17):1593-1604. PubMed ID: 31697206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical and bioanalytical considerations for establishing a depletion criterion for specificity testing during immunogenicity assessment of a biotherapeutic.
    Driscoll RO; Zhou L; Moxness M; Mytych D; Chirmule N; Jawa V
    AAPS J; 2013 Oct; 15(4):1160-7. PubMed ID: 23990502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-drug Antibody Sample Testing and Reporting Harmonization.
    Jani D; Marsden R; Gunsior M; Hay LS; Ward B; Cowan KJ; Azadeh M; Barker B; Cao L; Closson KR; Coble K; Dholakiya SL; Dusseault J; Hays A; Herl C; Hodsdon ME; Irvin SC; Kirshner S; Kolaitis G; Kulagina N; Kumar S; Lai CH; Lipari F; Liu S; Merdek KD; Moldovan IR; Mozaffari R; Pan L; Place C; Snoeck V; Manning MS; Stocker D; Tary-Lehmann M; Turner A; Vainshtein I; Verthelyi D; Williams WT; Yan H; Yan W; Yang L; Yang L; Zemo J; Zhong ZD
    AAPS J; 2022 Oct; 24(6):113. PubMed ID: 36307592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assays.
    Kubiak RJ; Zhang L; Zhang J; Zhu Y; Lee N; Weichold FF; Yang H; Abraham V; Akufongwe PF; Hewitt L; Robinson S; Liu W; Liu X; Patnaik MM; Spitz S; Wu Y; Roskos LK
    J Pharm Biomed Anal; 2013 Feb; 74():235-45. PubMed ID: 23245256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of in-study cut points to enable appropriate interpretation of clinical immunogenicity results.
    Brumm J; Peng K
    Bioanalysis; 2019 Sep; 11(17):1539-1541. PubMed ID: 31208203
    [No Abstract]   [Full Text] [Related]  

  • 17. Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.
    Goodman J; Cowen S; Devanarayan V; Egging D; Emrich T; Golob M; Kramer D; McNally J; Munday J; Nelson R; Pedras-Vasconcelos JA; Piironen T; Sickert D; Skibeli V; Fjording MS; Timmerman P
    Bioanalysis; 2018 Feb; 10(4):197-204. PubMed ID: 29345496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?
    Jordan G; Staack RF
    Bioanalysis; 2020 Jul; 12(14):1021-1031. PubMed ID: 32633539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Alternative Data Transformation Approach for ADA Cut Point Determination: Why Not Use a Weibull Transformation?
    Jordan G; Staack RF
    AAPS J; 2021 Aug; 23(5):97. PubMed ID: 34389881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.